[1] 劳海燕. 肾衰患者万古霉素的药代动力学特点的研究: proceedings of the 第十一次全国临床药理学学术大会论文集,[C]. 2008.
[2] 季闽春, 沈晓英, 杨耀芳.万古霉素的药代动力学研究进展[J]. 中国临床药理学杂志,2008,24(6)：4.
[3] Ludden T. Population pharmacokinetics[J]. The Journal of Clinical Pharmacology, 1988,28(12)：1059-1063.
[4] 贾运涛,蒋学华.群体药动学理论及其应用[J]. 中国药房， 2004,15(1)。
[5] Golper TA, Noonan HM, Elzinga L, et al. Vancomycin pharmacokinetics, renal handling, andnonrenal clearances in normal human subjects[J]. Clin Pharmacol Ther, 1988,43(5)： 565-570.
[6] Purwonugroho TA, Chulavatnatol S, Preechagoon Y, et al. Population pharmacokinetics ofvancomycin in Thai patients[J]. TheScientificWorldJournal, 2012,2012: 762649.
[7] Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin[J]. Clin InfectDis, 2006,42 Suppl 1: S35-39.
[8] Matzke G, Zhanel G, Guay D. Clinical pharmacokinetics of vancomycin[J]. Clinicalpharmacokinetics, 1986,11(4)： 257-282.
[9] Marsot A, Boulamery A, Bruguerolle B, et al. Vancomycin: a review of populationpharmacokinetic analyses[J]. Clin Pharmacokinet, 2012,51(1)： 1-13.
[10] Ducharme MP, Slaughter RL, Edwards DJ. Vancomycin pharmacokinetics in a patient population:effect of age, gender, and body weight[J]. Therapeutic drug monitoring, 1994,16(5)： 513-518.
[11] Manzoni P, Rizzollo S, Decembrino L, et al. Recent advances in prevention of sepsis in thepremature neonates in NICU[J]. Early human development, 2011,87 Suppl 1: S31-33.
[12] de Hoog M, Mouton JW, van den Anker JN. Vancomycin: pharmacokinetics and administrationregimens in neonates[J]. Clin Pharmacokinet, 2004,43(7)： 417-440.
[13] Allegaert K, Verbesselt R, Naulaers G, et al. Developmental pharmacology: neonates are not justsmall adults[J]. Acta clinica belgica, 2008,63(1)： 16-24.
[14] Pacifici GM, Allegaert K. Clinical pharmacokinetics of vancomycin in the neonate: a review[J].Clinics, 2012,67(7)： 831-837.
[15] Lietman PS, Schaad UB, McCracken Jr GH, et al. Clinical pharmacology and efficacy ofvancomycin in pediatric patients[J]. The Journal of pediatrics, 1980,96(1)： 119-126.
[16] Gross J, Kaplan S, Kramer W, et al. Vancomycin pharmacokinetics in premature infants[J].Pediatric pharmacology (New York, NY)， 1985,5(1)： 17.
[17] Frattarelli DA, Ergun H, Lulic-Botica M, et al. Vancomycin elimination in human infants withintrauterine growth retardation[J]. The Pediatric infectious disease journal, 2005,24(11)： 979-983.
[18] Lo Y-L, van Hasselt JG, Heng S-C, et al. Population pharmacokinetics of vancomycin inpremature Malaysian neonates: identification of predictors for dosing determination[J]. Antimicrobialagents and chemotherapy, 2010,54(6)： 2626-2632.
[19] Anderson BJ, Allegaert K, Van den Anker JN, et al. Vancomycin pharmacokinetics in pretermneonates and the prediction of adult clearance[J]. British journal of clinical pharmacology, 2007,63(1)：75-84.
[20] de Hoog M, Schoemaker RC, Mouton JW, et al. Vancomycin population pharmacokinetics inneonates[J]. Clinical Pharmacology Therapeutics, 2000,67(4)： 360-367.
[21] Oudin C, Vialet R, Boulamery A, et al. Vancomycin prescription in neonates and young infants:toward a simplified dosage[J]. Archives of Disease in Childhood-Fetal and Neonatal Edition,2011,96(5)： F365-F370.
[22] Asbury W, Darsey E, Rose W, et al. Vancomycin pharmacokinetics in neonates and infants: aretrospective evaluation[J]. The Annals of pharmacotherapy, 1993,27(4)： 490-496.
[23] Silva R, Reis E, Bispo M, et al. Pharmacokinetics: The Kinetic Profile of Vancomycin inNeonates[J]. Journal of pharmacy and pharmacology, 1998,50(11)： 1255-1260.
[24] Marqus‐Mi?ana MR, Saadeddin A, Peris JE. Population pharmacokinetic analysis ofvancomycin in neonates. A new proposal of initial dosage guideline[J]. British journal of clinicalpharmacology, 2010,70(5)： 713-720.
[25] Seay RE, Brundage RC, Jensen PD, et al. Population pharmacokinetics of vancomycin inneonates[J]. Clinical Pharmacology Therapeutics, 1994,56(2)： 169-175.
[26] Najjar TA, Al-Dhuwailie AA, Tekle A. Comparison of high-performance liquid chromatographywith fluorescence polarization immunoassay for the analysis of vancomycin in patients with chronicrenal failure[J]. Journal of Chromatography B: Biomedical Sciences and Applications, 1995,672(2)：295-299.
[27] 胡瑾瑜, 施耀国, 张菁,等. 万古霉素在健康老年人和年轻人的药代动力学[J]. 中国抗感染化疗杂志, 2003,3(3): 138-142.
[28] Sanchez J, Dominguez A, Lane J, et al. Population pharmacokinetics of vancomycin in adult andgeriatric patients: comparison of eleven approaches[J]. International journal of clinical pharmacologyand therapeutics, 2010,48(8)： 525-533.
[29] Mizokami F, Shibasaki M, Yoshizue Y, et al. Pharmacodynamics of vancomycin in elderlypatients aged 75 years or older with methicillin-resistant Staphylococcus aureus hospital-acquiredpneumonia[J]. Clinical interventions in aging, 2013,8: 1015-1021.
[30] Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adultpatients: a consensus review of the American Society of Health-System Pharmacists, the InfectiousDiseases Society of America, and the Society of Infectious Diseases Pharmacists[J]. American Journalof Health-System Pharmacy, 2009,66(1)： 82-98.
[31] Martin JH, Norris R, Barras M, et al. Therapeutic monitoring of vancomycin in adult patients: Aconsensus review of the American Society of Health-System Pharmacists, the Infectious DiseasesSociety of America, and the Society of Infectious Diseases Pharmacists[J]. The Clinical BiochemistReviews, 2010,31(1)： 21.
[32] Hazlewood KA, Brouse SD, Pitcher WD, et al. Vancomycin-associated nephrotoxicity: graveconcern or death by character assassination?[J]. The American journal of medicine, 2010,123(2)： 182.e181-182. e187.
[33] Yasuhara M, Iga T, Zenda H, et al. Population pharmacokinetics of vancomycin in Japanese adultpatients[J]. Therapeutic drug monitoring, 1998,20(2)： 139-148.
[34] Revilla N, Martn‐Surez A, Prez MP, et al. Vancomycin dosing assessment in intensive care unitpatients based on a population pharmacokinetic/pharmacodynamic simulation[J]. British journal ofclinical pharmacology, 2010,70(2)： 201-212.
[35] Schaedeli F, Uehlinger DE. Urea kinetics and dialysis treatment time predict vancomycinelimination during high-flux hemodialysisast[J]. Clinical Pharmacology Therapeutics, 1998,63(1)：26-38.
[36] 葛卫红,顾勤,贺玲,等.肾衰患者连续性血液滤过时万古霉素的药效学及药动学研究[J]. 中国药学杂志， 2001,36(11)： 753-755.
[37] DelDot ME, Lipman J, Tett SE. Vancomycin pharmacokinetics in critically ill patients receivingcontinuous venovenous haemodiafiltration[J]. British journal of clinical pharmacology, 2004,58(3)：259-268.
以上就是查字典大学网为同学们带来的“药学硕士论文参考文献推荐”内容了，希望看完能够带给大家一些力量，对同学的生活有所启示，更多内容在这里，请继续关注我们。